$LLY

$LLY · Schwab Network · 2026-11-16

AI 摘要 · Schwab Network

Eli Lilly 具有一定防御性;随着减肥药持续上市,接下来是 Retatrutide/GLP-3,它可能成为一款颠覆格局、消灭竞争的产品。说话者称 LLY 与 Google 一样有 10% 至 20% 的上涨空间,两者可因不同原因、在不同情境下跑赢。

看涨
《Adam Coons On Defense; "No Touch" on NVDA, Avoiding HD and LOW Pre-Earnings》
Schwab Network发布 2026-11-16 · 3 段内容

播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策

05:21/ —打开原视频

逐段跳播

3 段内容

像 Google 这样你喜欢的股票。它财报后确实出现了下跌,但整体处于某种上行趋势。还有 Eli Lily。你认为这两只股票都有 10% 到 20% 的上涨潜力吗?

Share like Google that you liked. I mean, it saw that decline after the earnings, but it was in a somewhat upward trend. And Eli Lily. Do you think both of these stocks have a 10 to 20% upside potential?

至于 Eli Lilly,它同样算是一只偏防御性的股票,但他们推出的产品,以及我们看到各种减肥药不断推出。我相信“Retatrotide”是下一个即将投产的产品。有人称它为“GLP-3”。

这款药很可能成为他们在这个领域的颠覆性产品,并可能淘汰其余竞争对手。

As for Eli Lilly, it is once again a somewhat defensive stock , but the products they are putting forward and we see a continuation of the introduction of various obesity drugs.

I believe "Retatrotide" is next in the production line. Some people call it "GLP-3". This drug is likely to be a game-changer for them in this field, and may eliminate the rest of the competition.

所以是的,这两只股票,出于不同的原因、在不同的情境下,我们相信它们确实有能力跑赢大盘。

So yes, both stocks, for different reasons and in different scenarios, we believe are truly capable of outperforming.

这个频道对 $LLY 的历次判断

Schwab Network 在这只股票上共 7 条判断,这里只列相邻的几条。

跨洋听风